Stability of Reconstituted Fibrinogen Concentrate in Hemostatic Function and Concentration

被引:1
|
作者
Peng, Henry T. [1 ]
Beckett, Andrew [2 ,3 ]
机构
[1] Toronto Res Ctr, Def Res & Dev Canada, Toronto, ON M3K 2C9, Canada
[2] McGill Univ, Dept Natl Def, Montreal, PQ H3Z 2G5, Canada
[3] Royal Canadian Med Serv, Dept Natl Def, Ottawa, ON K1A 0K2, Canada
关键词
D O I
10.1093/milmed/usaa409
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Canadian Armed Forces adopted fibrinogen concentrate (RiaSTAP) for hemostatic resuscitation in the far-forward combat setting, given its potential benefits of reducing blood loss, blood transfusion and mortality, and its long storage stability and high portability. The current guidance recommends that RiaSTAP should be administered within 8 hours after reconstitution when stored at room temperature. However, little information about its stability is available. There is also a need to investigate the stability and efficacy of RiaSTAP after reconstitution and exposure to extreme temperatures in which our forces may operate. Materials and Methods: RiaSTAP was reconstituted as per manufacturer's instruction and stored at specific temperatures (-20 degrees C, 4 degrees C, 22 degrees C, 35 degrees C, 42 degrees C, or 50 degrees C) for up to 6 months. Reconstituted RiaSTAP was also oscillated on a rocker at 18 rpm under 22 degrees C and 50 degrees C. Its hemostatic function was measured using rotational thromboelastometry performed with RiaSTAP-spiked whole blood. Fibrinogen concentrations were measured by a commercial enzyme-linked immunosorbent assay (ELISA) kit. Gel electrophoresis was also conducted for initial and stored samples. Results: We found no change to the hemostatic function of reconstituted RiaSTAP after storage at -20 degrees C for 6 months. At 4 degrees C, no obvious changes to the hemostatic effect of reconstituted RiaSTAP relative to 0 hours were seen until 1,680 hours. At 22 degrees C, a remarkable decrease began after storage for 168 hours. Storage at 35 degrees C significantly decreased the hemostatic effect after 144 hours, while the storage at 42 degrees C resulted in decreased hemostatic function after 72 hours. Finally, storage at 50 degrees C for 8 hours resulted in complete loss of hemostatic function. Compared to the hemostatic activity, the fibrinogen concentration for reconstituted RiaSTAP showed less change over time. No apparent decline in fibrinogen concentration was seen after storage at -20 degrees C for 6 months and at 4 degrees C for 1,680 hours. At 22 degrees C, there were no clear alterations until 792 hours. There was a decline in fibrinogen concentration at 35 degrees C and 42 degrees C after 672 and 600 hours of storage, respectively. At 50 degrees C, little amount of fibrinogen was detected by ELISA at 8 hours. Similar changes in the hemostatic effect and fibrinogen concentration over time were observed under the rocking condition in comparison with the static condition at the same temperature. The gel electrophoresis confirmed fibrinogen degradation which increased with storage temperature and time. Conclusions: The stability of reconstituted RiaSTAP decreases with increasing storage temperature. The hemostatic function deteriorated before fibrinogen concentration and integrity were significantly altered at all temperatures for the study period except at 50 degrees C where there was a rapid decline in both hemostatic function and fibrinogen concentration. Sample oscillation did not significantly affect its stability. The shelf life of reconstituted RiaSTAP may, therefore, be recommended accordingly when stored at different temperatures and extended to 6 days at room temperature provided that sterility is maintained.
引用
收藏
页码:E456 / E462
页数:7
相关论文
共 50 条
  • [1] Fibrinogen concentrate - a potential universal hemostatic agent
    Fenger-Eriksen, Christian
    Ingerslev, Jorgen
    Sorensen, Benny
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (10) : 1325 - 1333
  • [2] Viscosity of reconstituted milk protein concentrate solutions as a function of shear, temperature and concentration
    O'Donnell, S.
    Butler, F.
    Developments in Chemical Engineering and Mineral Processing, 1999, 7 (1-2): : 131 - 139
  • [3] Recovery of fibrinogen plasma level after administration of fibrinogen concentrate for hemostatic therapy in aortic surgery
    Rahe-Meyer, N.
    Tanaka, K.
    Goerlinger, K.
    Pichlmaier, M.
    Osthaus, A.
    Piepenbrock, S.
    Solomon, C.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1003 - 1004
  • [4] LOCAL HEMOSTASIS AFTER TOOTH EXTRACTION IN PATIENTS WITH ABNORMAL HEMOSTATIC FUNCTION - USE OF HUMAN-FIBRINOGEN CONCENTRATE
    BAUDO, F
    DECATALDO, F
    GATTI, R
    LANDONIO, G
    MUTI, G
    SCOLARI, G
    HAEMOSTASIS, 1985, 15 (06) : 402 - 404
  • [5] Heat stability of reconstituted milk protein concentrate powders
    Crowley, Shane V.
    Megemont, Mathilde
    Gazi, Inge
    Kelly, Alan L.
    Huppertz, Thom
    O'Mahony, James A.
    INTERNATIONAL DAIRY JOURNAL, 2014, 37 (02) : 104 - 110
  • [7] FIBRINOGEN CONCENTRATE STABILITY UNDER DIFFERENT TEMPERATURES AND DURATIONS
    Martini, W. Z.
    DeGuzman, R.
    Rodriguez, C.
    Bice, L.
    Polykratis, I. A.
    Cap, A.
    Dubick, M. A.
    SHOCK, 2016, 45 (06): : 92 - 92
  • [8] Hemostatic Function of Stored Buffy Coat Platelet Concentrate in Plasma Treated with Riboflavin/UV Light and Reconstituted with Fresh-frozen Plasma
    Arbaeen, A. F.
    Schubert, P.
    Serrano, K.
    Devine, D.
    TRANSFUSION, 2016, 56 : 69A - 69A
  • [9] Fibrinogen concentrate - a potential universal hemostatic agent (vol 9, pg 1325, 2009)
    Fenger-Eriksen, C.
    Ingerslev, J.
    Sorensen, B.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (02) : 299 - 299
  • [10] Hemostatic effect of fibrinogen concentrate on traumatic massive hemorrhage: a propensity score matching study
    Heo, Yoonjung
    Chang, Sung Wook
    Lee, Seok Won
    Ma, Dae Sung
    Kim, Dong Hun
    TRAUMA SURGERY & ACUTE CARE OPEN, 2024, 9 (01)